©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
World J Clin Pediatr. Mar 9, 2026; 15(1): 111093
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.111093
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.111093
Efficacy and safety of dual-targeted therapy in children with inflammatory bowel disease: Retrospective cohort study
Tatiana Gabrusskaya, Elena Kornienko, Department of Children's Diseases named after Professor I. M. Vorontsov, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Sankt-Peterburg, Russia
Natalia Ulanova, Elena Shilova, Natalia Volkova, Sofia Kilina, Department of Gastroenterology, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Sankt-Peterburg, Russia
Mikhail Kostik, Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Sankt-Peterburg, Russia
Author contributions: Gabrusskaya T conducted a review of the published articles, performed data analysis, and provided interpretation; Gabrusskaya T, Ulanova N, Shilova E, Volkova N, and Kilina S contributed to software, resources, and data curation; Kornienko E designed the research study and participated in the interpretation of the results; Kostik M performed statistical analyses and contributed to the critical review of the manuscript; all authors have read and agreed to the published version of the manuscript.
Institutional review board statement: The study protocol was approved by the Institutional Review Board of Saint Petersburg State Pediatric Medical University on February 25, 2025. The study adhered to the ethical principles of the Declaration of Helsinki, ensuring the protection of participants’ rights. All data were collected and processed anonymously.
Informed consent statement: Informed consent was obtained from all subjects involved in the study.
Conflict-of-interest statement: The authors declare no conflicts of interest.
STROBE statement: The authors have read the STROBE Statement - checklist of items, and the manuscript was prepared and revised according to the STROBE Statement - checklist of items.
Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Corresponding author: Mikhail Kostik, MD, PhD, Professor, Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Lytovskaya 2, Saint Petersburg 194100, Sankt-Peterburg, Russia. kost-mikhail@yandex.ru
Received: June 24, 2025
Revised: July 27, 2025
Accepted: November 7, 2025
Published online: March 9, 2026
Processing time: 256 Days and 20.2 Hours
Revised: July 27, 2025
Accepted: November 7, 2025
Published online: March 9, 2026
Processing time: 256 Days and 20.2 Hours
Core Tip
Core Tip: We conducted a single-center retrospective cohort study on 18 children with inflammatory bowel disease who received dual-targeted therapy (DTT) with biologics and Janus kinase inhibitors. Clinical remission was achieved in 9 out of 20 (45%) and 13 out of 20 (65%) DTT courses at three months and six months (M6), respectively. In contrast, laboratory and endoscopic remission were achieved in 8 out of 20 (40%) and 9 out of 17 (53%) treatment courses, respectively, within M6 of treatment initiation. Predictors of poor response to DTT were perianal lesions and upper gastrointestinal tract involvement in Crohn’s disease. Early onset of inflammatory bowel diseases was associated with higher remission rates.